AMG 386 + AMG 386 Placebo + Paclitaxel + Paclitaxel
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Fallopian Tube Cancer
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Trial Timeline
Nov 1, 2010 → Dec 1, 2016
NCT ID
NCT01204749About AMG 386 + AMG 386 Placebo + Paclitaxel + Paclitaxel
AMG 386 + AMG 386 Placebo + Paclitaxel + Paclitaxel is a phase 3 stage product being developed by Amgen for Fallopian Tube Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01204749. Target conditions include Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01204749 | Phase 3 | Completed |
Competing Products
20 competing products in Fallopian Tube Cancer